董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua M. Murray | 男 | Director | 41 | 76.45万美元 | 13.88 | 2025-10-10 |
| Kimberly Park | 女 | Director | 61 | 76.50万美元 | 19.00 | 2025-10-10 |
| Daniel N. Swisher | 男 | Director | 62 | 未披露 | 未持股 | 2025-10-10 |
| James N. Wilson | 男 | Chairman of the Board | 81 | 129.29万美元 | 301.62 | 2025-10-10 |
| Joseph K. Belanoff | 男 | Director,Chief Executive Officer and President | 67 | 1530.36万美元 | 692.89 | 2025-10-10 |
| G. Leonard Baker, Jr. | 男 | Director | 82 | 76.80万美元 | 555.02 | 2025-10-10 |
| Daniel N. Swisher, Jr. | 男 | Director | 62 | 76.20万美元 | 13.90 | 2025-10-10 |
| David L. Mahoney | 男 | Director | 71 | 78.45万美元 | 152.88 | 2025-10-10 |
| Gregg Alton | 男 | Director | 59 | 78.70万美元 | 19.00 | 2025-10-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Atabak Mokari | 男 | Chief Financial Officer and Treasurer | 48 | 613.57万美元 | 68.84 | 2025-10-10 |
| William Guyer | 男 | Chief Development Officer | 57 | 634.04万美元 | 63.94 | 2025-10-10 |
| Hazel Hunt | 女 | Chief Scientific Officer | 65 | 未披露 | 未持股 | 2025-10-10 |
| Joseph D. Lyon | 男 | Chief Accounting and Technology Officer | 47 | 未披露 | 未持股 | 2025-10-10 |
| Sean Maduck | 男 | President, Corcept Endocrinology | 48 | 620.86万美元 | 182.53 | 2025-10-10 |
| Charles Robb | 男 | Chief Business Officer and Secretary | 62 | 未披露 | 未持股 | 2025-10-10 |
| Joseph K. Belanoff | 男 | Director,Chief Executive Officer and President | 67 | 1530.36万美元 | 692.89 | 2025-10-10 |
| G. Charles Robb | 男 | Chief Business Officer and Secretary | 62 | 638.05万美元 | 169.00 | 2025-10-10 |
董事简历
中英对照 | 中文 | 英文- Joshua M. Murray
-
Joshua M. Murray自2021年6月起担任Corcept Therapeutics Incorporated（纳斯达克股票代码：CORT）的董事会成员，该公司是一家商业阶段公司，从事通过调节激素皮质醇的作用来发现和开发治疗严重的内分泌、肿瘤、代谢和神经系统疾病的药物，目前担任其审计委员会成员。Murray先生自2025年10月起担任私营制药公司Par Health，Inc.的董事会成员，目前担任审计委员会主席、提名和公司治理委员会成员以及质量和合规委员会成员。
Joshua M. Murray has served as a member of the board of directors of Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, since June 2021, and currently serves on its Audit Committee. Mr. Murray has served as a member of the board of directors of Par Health, Inc., a privately held pharmaceutical company, since October 2025, and currently serves as Chair of the Audit Committee, as a member of the Nominating and Corporate Governance Committee and as a member of the Quality and Compliance Committee. - Joshua M. Murray自2021年6月起担任Corcept Therapeutics Incorporated（纳斯达克股票代码：CORT）的董事会成员，该公司是一家商业阶段公司，从事通过调节激素皮质醇的作用来发现和开发治疗严重的内分泌、肿瘤、代谢和神经系统疾病的药物，目前担任其审计委员会成员。Murray先生自2025年10月起担任私营制药公司Par Health，Inc.的董事会成员，目前担任审计委员会主席、提名和公司治理委员会成员以及质量和合规委员会成员。
- Joshua M. Murray has served as a member of the board of directors of Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, since June 2021, and currently serves on its Audit Committee. Mr. Murray has served as a member of the board of directors of Par Health, Inc., a privately held pharmaceutical company, since October 2025, and currently serves as Chair of the Audit Committee, as a member of the Nominating and Corporate Governance Committee and as a member of the Quality and Compliance Committee.
- Kimberly Park
-
Kimberly Park，自2019年9月起担任董事会成员。她于2014年至2018年担任默沙东公司客户战略和创新全球副总裁，还于1997年至2005年在默沙东担任全球和美国领导职务，包括美国管理式护理营销副总裁。2005年至2014年，朴女士在强生公司担任高级领导职务，包括2010年至2014年担任杨森医疗保健创新的创始合伙人和全球副总裁，以及2005年至2010年担任杨森制药公司初级保健销售和营销的美国副总裁。在加入默沙东之前，Park女士曾在葛兰素史克（GlaxoSmithKline plc）担任美国和全球商业领导职务。Park女士自2018年起担任建筑材料行业设备制造商Besser Company的董事会成员，自2021年1月起担任为医疗器械和航空航天行业提供产品的精密制造公司TechETch的董事会成员。她还担任三个非营利组织的董事会成员，并且是费城资本与技术联盟的导师。朴女士获得了密歇根大学的国际商务学士学位。
Kimberly Park,has served as a member of Board since September 2019. She was Global Vice President of Customer Strategy and Innovation at Merck & Co. from 2014 to 2018 and also held global and U.S. leadership roles at Merck from 1997 to 2005, including U.S. Vice President of Managed Care Marketing. From 2005 to 2014, Ms. Park served in senior leadership roles at Johnson and Johnson, including Founding Partner and Global Vice President of Janssen Healthcare Innovation from 2010 to 2014 and U.S. Vice President of Primary Care Sales and Marketing of Janssen Pharmaceuticals from 2005 to 2010. Prior to joining Merck, Ms. Park held U.S. and global commercial leadership positions at GlaxoSmithKline plc. Ms. Park has served on the board of directors of Besser Company, a manufacturer of equipment for the building materials industry, since 2018, and TechEtch, a precision manufacturing company that supplies medical device and aerospace industries, since January 2021. She also serves as a board member for three non-profit organizations and is a mentor for Philadelphia Alliance of Capital and Technology. Ms. Park received her B.A. in International Business from the University of Michigan. - Kimberly Park，自2019年9月起担任董事会成员。她于2014年至2018年担任默沙东公司客户战略和创新全球副总裁，还于1997年至2005年在默沙东担任全球和美国领导职务，包括美国管理式护理营销副总裁。2005年至2014年，朴女士在强生公司担任高级领导职务，包括2010年至2014年担任杨森医疗保健创新的创始合伙人和全球副总裁，以及2005年至2010年担任杨森制药公司初级保健销售和营销的美国副总裁。在加入默沙东之前，Park女士曾在葛兰素史克（GlaxoSmithKline plc）担任美国和全球商业领导职务。Park女士自2018年起担任建筑材料行业设备制造商Besser Company的董事会成员，自2021年1月起担任为医疗器械和航空航天行业提供产品的精密制造公司TechETch的董事会成员。她还担任三个非营利组织的董事会成员，并且是费城资本与技术联盟的导师。朴女士获得了密歇根大学的国际商务学士学位。
- Kimberly Park,has served as a member of Board since September 2019. She was Global Vice President of Customer Strategy and Innovation at Merck & Co. from 2014 to 2018 and also held global and U.S. leadership roles at Merck from 1997 to 2005, including U.S. Vice President of Managed Care Marketing. From 2005 to 2014, Ms. Park served in senior leadership roles at Johnson and Johnson, including Founding Partner and Global Vice President of Janssen Healthcare Innovation from 2010 to 2014 and U.S. Vice President of Primary Care Sales and Marketing of Janssen Pharmaceuticals from 2005 to 2010. Prior to joining Merck, Ms. Park held U.S. and global commercial leadership positions at GlaxoSmithKline plc. Ms. Park has served on the board of directors of Besser Company, a manufacturer of equipment for the building materials industry, since 2018, and TechEtch, a precision manufacturing company that supplies medical device and aerospace industries, since January 2021. She also serves as a board member for three non-profit organizations and is a mentor for Philadelphia Alliance of Capital and Technology. Ms. Park received her B.A. in International Business from the University of Michigan.
- Daniel N. Swisher
-
Daniel N. Swisher，自2015年6月起担任董事会成员。自2024年5月以来，Swisher先生一直担任NodThera，Inc.的首席执行官和董事会成员，该公司是一家私人临床阶段的生物技术公司，开发NLRP3炎症小体抑制剂来治疗慢性炎症性疾病。2018年1月至2023年9月，担任爵士制药总裁兼首席运营官。2003年至2017年12月，他担任临床阶段生物制药公司Sunesis Pharmaceuticals的首席执行官和董事会成员，2005年至2017年，他还是该公司的总裁。2001年加入新宙邦，在此之前曾担任公司首席商务官、首席财务官。在此之前，Swisher先生曾于1992年至2001年在制药和医疗系统公司ALZA Corporation担任过一系列高级管理职务。Swisher先生自2013年起担任上市生物制药公司Cerus Corporation的董事会主席。Swisher先生获得了耶鲁大学的学士学位和斯坦福大学商学院的工商管理硕士学位。
Daniel N. Swisher,has served as a member of Board since June 2015. Since May 2024, Mr. Swisher has served as Chief Executive Officer and a member of the board of NodThera, Inc., a private clinical-stage biotech developing NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. He was President and Chief Operating Officer of Jazz Pharmaceuticals from January 2018 to September 2023. From 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a clinical-stage biopharmaceutical company and from 2005 to 2017, he was also its President. He joined Sunesis in 2001 and had previously served as the company's Chief Business Officer and Chief Financial Officer. Prior to that, Mr. Swisher held a range of senior management roles at ALZA Corporation, a pharmaceutical and medical systems company, from 1992 to 2001. Mr. Swisher has served as Chairman of the board of directors of Cerus Corporation, a publicly traded biopharmaceutical company, since 2013. Mr. Swisher received his B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business. - Daniel N. Swisher，自2015年6月起担任董事会成员。自2024年5月以来，Swisher先生一直担任NodThera，Inc.的首席执行官和董事会成员，该公司是一家私人临床阶段的生物技术公司，开发NLRP3炎症小体抑制剂来治疗慢性炎症性疾病。2018年1月至2023年9月，担任爵士制药总裁兼首席运营官。2003年至2017年12月，他担任临床阶段生物制药公司Sunesis Pharmaceuticals的首席执行官和董事会成员，2005年至2017年，他还是该公司的总裁。2001年加入新宙邦，在此之前曾担任公司首席商务官、首席财务官。在此之前，Swisher先生曾于1992年至2001年在制药和医疗系统公司ALZA Corporation担任过一系列高级管理职务。Swisher先生自2013年起担任上市生物制药公司Cerus Corporation的董事会主席。Swisher先生获得了耶鲁大学的学士学位和斯坦福大学商学院的工商管理硕士学位。
- Daniel N. Swisher,has served as a member of Board since June 2015. Since May 2024, Mr. Swisher has served as Chief Executive Officer and a member of the board of NodThera, Inc., a private clinical-stage biotech developing NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. He was President and Chief Operating Officer of Jazz Pharmaceuticals from January 2018 to September 2023. From 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a clinical-stage biopharmaceutical company and from 2005 to 2017, he was also its President. He joined Sunesis in 2001 and had previously served as the company's Chief Business Officer and Chief Financial Officer. Prior to that, Mr. Swisher held a range of senior management roles at ALZA Corporation, a pharmaceutical and medical systems company, from 1992 to 2001. Mr. Swisher has served as Chairman of the board of directors of Cerus Corporation, a publicly traded biopharmaceutical company, since 2013. Mr. Swisher received his B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
- James N. Wilson
-
James N. Wilson，自1999年他担任公司董事和董事会主席。此外，自2005年他一直NuGEN Technologies公司（基因组分析系统的提供者）的董事会主席。从2002年到2009年，他曾担任Amylin制药公司（一家公开上市的生物制药公司）的首席独立董事，1996至2001年他是阿米拉医药公司的董事会主席，该公司后来被Hoffmann-La Roche公司收购。从1991年至1994年，他为Syntex公司的首席运营官，该公司后来被 Roche 控股有限公司收购。从1989年至1990年他为Neurex公司的董事长兼首席执行官，该公司被Elan公司收购了 ，以及1982年至1988年他是LifeScan公司的首席执行官，该公司被强生公司收购。他接受了亚利桑那大学的文学士学位和工商管理硕士学位。
James N. Wilson,has served as a director and as Chairman of Board since 1999. From 2005 to 2018, he was also a member of the board of directors of NuGEN Technologies, Inc., a provider of systems for genomic analysis. From 2002 to 2009, Mr. Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the board of directors of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr. Wilson was Chief Operating Officer of Syntex Corporation, which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr. Wilson was Chairman and Chief Executive Officer of Neurex Corporation, which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr. Wilson received his B.A. and M.B.A. from the University of Arizona. - James N. Wilson，自1999年他担任公司董事和董事会主席。此外，自2005年他一直NuGEN Technologies公司（基因组分析系统的提供者）的董事会主席。从2002年到2009年，他曾担任Amylin制药公司（一家公开上市的生物制药公司）的首席独立董事，1996至2001年他是阿米拉医药公司的董事会主席，该公司后来被Hoffmann-La Roche公司收购。从1991年至1994年，他为Syntex公司的首席运营官，该公司后来被 Roche 控股有限公司收购。从1989年至1990年他为Neurex公司的董事长兼首席执行官，该公司被Elan公司收购了 ，以及1982年至1988年他是LifeScan公司的首席执行官，该公司被强生公司收购。他接受了亚利桑那大学的文学士学位和工商管理硕士学位。
- James N. Wilson,has served as a director and as Chairman of Board since 1999. From 2005 to 2018, he was also a member of the board of directors of NuGEN Technologies, Inc., a provider of systems for genomic analysis. From 2002 to 2009, Mr. Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the board of directors of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr. Wilson was Chief Operating Officer of Syntex Corporation, which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr. Wilson was Chairman and Chief Executive Officer of Neurex Corporation, which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr. Wilson received his B.A. and M.B.A. from the University of Arizona.
- Joseph K. Belanoff
-
Joseph K. Belanoff，他是公司的共同创办人，自1999年起担任公司董事会成员和首席执行官，自2014年1月1日为公司的总裁。他目前是临床教员，自1992年以来在斯坦福大学的精神病学和行为科学系担任多个职位。他收到了阿默斯特学院的学士学位和哥伦比亚大学的医生和外科医生学院的医学博士学位。
Joseph K. Belanoff,is a co-founder of Company and has served as a member of Board and Chief Executive Officer since Corcept's inception in 1999, and as President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions in the Department of Psychiatry and Behavioral Sciences since 1992. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University's College of Physicians & Surgeons. - Joseph K. Belanoff，他是公司的共同创办人，自1999年起担任公司董事会成员和首席执行官，自2014年1月1日为公司的总裁。他目前是临床教员，自1992年以来在斯坦福大学的精神病学和行为科学系担任多个职位。他收到了阿默斯特学院的学士学位和哥伦比亚大学的医生和外科医生学院的医学博士学位。
- Joseph K. Belanoff,is a co-founder of Company and has served as a member of Board and Chief Executive Officer since Corcept's inception in 1999, and as President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions in the Department of Psychiatry and Behavioral Sciences since 1992. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University's College of Physicians & Surgeons.
- G. Leonard Baker, Jr.
-
G. Leonard Baker, Jr.自1999年以来他担任公司董事会成员。自1973年以来他一直萨特山风险投资公司（加州帕罗奥图的风险投资公司）的普通合伙人的常务董事。他目前服务于优酷公司（一家上市公司）董事会，担任审核及薪酬委员会成员。他还担任多间私人公司的董事。他接受了耶鲁大学的文学士学位和斯坦福大学MBA学位。
G. Leonard Baker, Jr. has served as a member of Board since 1999. Since 1973 Mr. Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, California. Mr. Baker currently serves on the boards of a number of private companies. He received his B.A. from Yale University and his M.B.A. from Stanford University. - G. Leonard Baker, Jr.自1999年以来他担任公司董事会成员。自1973年以来他一直萨特山风险投资公司（加州帕罗奥图的风险投资公司）的普通合伙人的常务董事。他目前服务于优酷公司（一家上市公司）董事会，担任审核及薪酬委员会成员。他还担任多间私人公司的董事。他接受了耶鲁大学的文学士学位和斯坦福大学MBA学位。
- G. Leonard Baker, Jr. has served as a member of Board since 1999. Since 1973 Mr. Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, California. Mr. Baker currently serves on the boards of a number of private companies. He received his B.A. from Yale University and his M.B.A. from Stanford University.
- Daniel N. Swisher, Jr.
-
Daniel N. Swisher, Jr.于2018年1月被任命为Jazz Pharmaceuticals Public Limited Company总裁，并从该日期起担任Jazz Pharmaceuticals Public Limited Company首席运营官至2021年5月和2022年11月至今。2003年12月至2017年12月，他担任Sunesis Pharmaceuticals, Inc.（一家生物制药公司，专注于开发血液和实体肿瘤恶性肿瘤的新型靶向癌症治疗药物）的首席执行官兼董事会成员。2001年至2003年，他还担任Sunesis的首席商务官和首席财务官。2001年之前，他曾担任各种管理职务，包括1992年至2001年担任ALZA Corporation的销售和营销高级副总裁。他目前担任Cerus公司（一家专注于输血安全领域的生物医学产品公司）的董事会主席，以及concept Therapeutics公司（一家专注于皮质醇调节疗法以解决代谢和其他严重医疗状况的制药公司）的董事会成员。他获得了耶鲁大学的学士学位和斯坦福大学商学院的工商管理硕士学位。
Daniel N. Swisher, Jr.,was appointed Jazz Pharmaceuticals Public Limited Company President as of January 2018 and also served as Jazz Pharmaceuticals Public Limited Company Chief Operating Officer from that date until May 2021 and from November 2022 to present. From December 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairperson of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business. - Daniel N. Swisher, Jr.于2018年1月被任命为Jazz Pharmaceuticals Public Limited Company总裁，并从该日期起担任Jazz Pharmaceuticals Public Limited Company首席运营官至2021年5月和2022年11月至今。2003年12月至2017年12月，他担任Sunesis Pharmaceuticals, Inc.（一家生物制药公司，专注于开发血液和实体肿瘤恶性肿瘤的新型靶向癌症治疗药物）的首席执行官兼董事会成员。2001年至2003年，他还担任Sunesis的首席商务官和首席财务官。2001年之前，他曾担任各种管理职务，包括1992年至2001年担任ALZA Corporation的销售和营销高级副总裁。他目前担任Cerus公司（一家专注于输血安全领域的生物医学产品公司）的董事会主席，以及concept Therapeutics公司（一家专注于皮质醇调节疗法以解决代谢和其他严重医疗状况的制药公司）的董事会成员。他获得了耶鲁大学的学士学位和斯坦福大学商学院的工商管理硕士学位。
- Daniel N. Swisher, Jr.,was appointed Jazz Pharmaceuticals Public Limited Company President as of January 2018 and also served as Jazz Pharmaceuticals Public Limited Company Chief Operating Officer from that date until May 2021 and from November 2022 to present. From December 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairperson of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
- David L. Mahoney
-
David L. Mahoney，他是一名私人投资者，自2004年7月起担任董事会成员。从1999年到2001年，他担任McKesson HBOC， Inc.（医疗供应管理和信息技术公司）的联合首席执行官，以及iMcKesson LLC（医疗管理和连接公司）的首席执行官。他于1990年加入McKesson Corporation，担任战略规划副总裁。在加入McKesson之前，他曾担任McKinsey & Company（一家管理咨询公司）的负责人（1981年至1990年）。2011年至2021年11月，他担任Adamas Pharmaceuticals（上市制药公司）的董事会成员，包括担任薪酬委员会主席和主席以及提名和治理委员会成员。2003年至2011年，他还担任赛门铁克审计委员会成员，2003年至2019年12月，担任董事会成员。他也是旧金山现代艺术博物馆的董事会成员，也是Schwab/Laudus Family of Funds的受托人。他在普林斯顿大学获得学士学位，在哈佛大学获得工商管理硕士学位。
David L. Mahoney,is a private investor who has served as a member of Board since July 2004. From 1999 to 2001, Mr. Mahoney served as co-Chief Executive Officer of McKesson HBOC, Inc., a healthcare supply management and information technology company, and as Chief Executive Officer of iMcKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr. Mahoney has served on the board of directors of Adamas Pharmaceuticals, a publicly traded pharmaceutical company, from 2011 to November 2021, including as Chairman, and chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011 and as a member of the board of directors from 2003 to December 2019. He also serves on the board of directors of the San Francisco Museum of Modern Art and is a Trustee of the Schwab/Laudus Family of Funds. Mr. Mahoney received his B.A. from Princeton University and his M.B.A. from Harvard University. - David L. Mahoney，他是一名私人投资者，自2004年7月起担任董事会成员。从1999年到2001年，他担任McKesson HBOC， Inc.（医疗供应管理和信息技术公司）的联合首席执行官，以及iMcKesson LLC（医疗管理和连接公司）的首席执行官。他于1990年加入McKesson Corporation，担任战略规划副总裁。在加入McKesson之前，他曾担任McKinsey & Company（一家管理咨询公司）的负责人（1981年至1990年）。2011年至2021年11月，他担任Adamas Pharmaceuticals（上市制药公司）的董事会成员，包括担任薪酬委员会主席和主席以及提名和治理委员会成员。2003年至2011年，他还担任赛门铁克审计委员会成员，2003年至2019年12月，担任董事会成员。他也是旧金山现代艺术博物馆的董事会成员，也是Schwab/Laudus Family of Funds的受托人。他在普林斯顿大学获得学士学位，在哈佛大学获得工商管理硕士学位。
- David L. Mahoney,is a private investor who has served as a member of Board since July 2004. From 1999 to 2001, Mr. Mahoney served as co-Chief Executive Officer of McKesson HBOC, Inc., a healthcare supply management and information technology company, and as Chief Executive Officer of iMcKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr. Mahoney has served on the board of directors of Adamas Pharmaceuticals, a publicly traded pharmaceutical company, from 2011 to November 2021, including as Chairman, and chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011 and as a member of the board of directors from 2003 to December 2019. He also serves on the board of directors of the San Francisco Museum of Modern Art and is a Trustee of the Schwab/Laudus Family of Funds. Mr. Mahoney received his B.A. from Princeton University and his M.B.A. from Harvard University.
- Gregg Alton
-
Gregg Alton，自2019年12月起担任董事。Alton先生在生物制药公司Gilead Sciences, Inc.任职20年后加入董事会。在Gilead，他担任临时首席执行官，负责公司的战略、增长和运营。作为首席患者官，他领导Gilead的患者外展和参与计划，以及公司在世界各地促进其药物获得的努力。他负责监督公司和医疗事务职能和发展中国家的访问计划，以及其数字患者解决方案和以患者为中心的结果组和某些国家的商业运营。他于1999年加入Gilead，并在公司担任多个职位，拥有法律、医疗事务、政策和商业方面的经验。他曾担任总法律顾问。在加入Gilead之前，他是Cooley Godward, LLP律师事务所的律师，在那里他专门从事医疗保健和信息技术公司的并购、企业合作和企业融资交易。他是concept Therapeutics Incorporated （NASDAQ： CORT）、Brii Biosciences Limited、Novavax, Inc. （NASDAQ： NVAX）、the Hepatitis Fund和the Boys and Girls Clubs of Oakland的董事会成员。Alton先生担任GARDP的董事会观察员。他还担任U.S. government's President's Advisory Council on HIV/AIDS成员，以及University of California at Berkeley文理学院顾问委员会成员。他持有the University of California at Berkeley的法律研究学士学位和Stanford University的法律学位。
Gregg Alton,has served as a director since December 2019. Mr. Alton joined the Board after serving for 20 years at the biopharmaceutical company Gilead Sciences, Inc. At Gilead, Mr. Alton served as interim Chief Executive Officer, responsible for the company's strategy, growth, and operations. As Chief Patient Officer, he led Gilead's patient outreach and engagement initiatives and the company's efforts to facilitate access to its medicines around the world. He oversaw the corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patient-centered outcomes groups and commercial operations in certain countries. Mr. Alton joined Gilead in 1999 and held a number of positions at the company with experience in legal, medical affairs,policy and commercial. He previously served as general counsel. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the Board of Directors of Corcept Therapeutics, Brii Biosciences, Novavax, Inc., the Hepatitis Fund, and the Boys and Girls Clubs of Oakland. Mr. Alton serves as a board observer for GARDP. He also serves on the U.S. government's President's Advisory Council on HIV/AIDS, and the advisory board for the UC Berkeley College of Letters & Science. Mr. Alton received a bachelor's degree in legal studies from the University of California at Berkeley and a law degree from Stanford University. - Gregg Alton，自2019年12月起担任董事。Alton先生在生物制药公司Gilead Sciences, Inc.任职20年后加入董事会。在Gilead，他担任临时首席执行官，负责公司的战略、增长和运营。作为首席患者官，他领导Gilead的患者外展和参与计划，以及公司在世界各地促进其药物获得的努力。他负责监督公司和医疗事务职能和发展中国家的访问计划，以及其数字患者解决方案和以患者为中心的结果组和某些国家的商业运营。他于1999年加入Gilead，并在公司担任多个职位，拥有法律、医疗事务、政策和商业方面的经验。他曾担任总法律顾问。在加入Gilead之前，他是Cooley Godward, LLP律师事务所的律师，在那里他专门从事医疗保健和信息技术公司的并购、企业合作和企业融资交易。他是concept Therapeutics Incorporated （NASDAQ： CORT）、Brii Biosciences Limited、Novavax, Inc. （NASDAQ： NVAX）、the Hepatitis Fund和the Boys and Girls Clubs of Oakland的董事会成员。Alton先生担任GARDP的董事会观察员。他还担任U.S. government's President's Advisory Council on HIV/AIDS成员，以及University of California at Berkeley文理学院顾问委员会成员。他持有the University of California at Berkeley的法律研究学士学位和Stanford University的法律学位。
- Gregg Alton,has served as a director since December 2019. Mr. Alton joined the Board after serving for 20 years at the biopharmaceutical company Gilead Sciences, Inc. At Gilead, Mr. Alton served as interim Chief Executive Officer, responsible for the company's strategy, growth, and operations. As Chief Patient Officer, he led Gilead's patient outreach and engagement initiatives and the company's efforts to facilitate access to its medicines around the world. He oversaw the corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patient-centered outcomes groups and commercial operations in certain countries. Mr. Alton joined Gilead in 1999 and held a number of positions at the company with experience in legal, medical affairs,policy and commercial. He previously served as general counsel. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the Board of Directors of Corcept Therapeutics, Brii Biosciences, Novavax, Inc., the Hepatitis Fund, and the Boys and Girls Clubs of Oakland. Mr. Alton serves as a board observer for GARDP. He also serves on the U.S. government's President's Advisory Council on HIV/AIDS, and the advisory board for the UC Berkeley College of Letters & Science. Mr. Alton received a bachelor's degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.
高管简历
中英对照 | 中文 | 英文- Atabak Mokari
Atabak Mokari，Mokari先生于2016年7月成为我们公司发展的首席财务官兼Vice President。加入公司之前，Mokari从2013年9月到2016年7月担任Wells Fargo Securities高级投资银行家，从2009年9月到2013年7月担任UBS高级投资银行家，从2005年7月到2009年2月担任Credit Suisse高级投资银行家。Mokari先生还在Olympus Partners，and Bowles Hollowell Conner担任职位。Mokari先生在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，在杜克大学（Duke University）获得化学和生物学学士学位。
Atabak Mokari, Mr. Mokari became our Chief Financial Officer and Vice President of Corporate Development in July 2016. Prior to joining the Company, Mr. Mokari was a senior investment banker at Wells Fargo Securities from September 2013 to July 2016 at UBS from September 2009 to July 2013 and at Credit Suisse from July 2005 to February 2009. Mr. Mokari also held positions at Olympus Partners, and Bowles Hollowell Conner. Mr. Mokari earned his MBA from The Tuck School of Business at Dartmouth and BS in Chemistry and Biology from Duke University.- Atabak Mokari，Mokari先生于2016年7月成为我们公司发展的首席财务官兼Vice President。加入公司之前，Mokari从2013年9月到2016年7月担任Wells Fargo Securities高级投资银行家，从2009年9月到2013年7月担任UBS高级投资银行家，从2005年7月到2009年2月担任Credit Suisse高级投资银行家。Mokari先生还在Olympus Partners，and Bowles Hollowell Conner担任职位。Mokari先生在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，在杜克大学（Duke University）获得化学和生物学学士学位。
- Atabak Mokari, Mr. Mokari became our Chief Financial Officer and Vice President of Corporate Development in July 2016. Prior to joining the Company, Mr. Mokari was a senior investment banker at Wells Fargo Securities from September 2013 to July 2016 at UBS from September 2009 to July 2013 and at Credit Suisse from July 2005 to February 2009. Mr. Mokari also held positions at Olympus Partners, and Bowles Hollowell Conner. Mr. Mokari earned his MBA from The Tuck School of Business at Dartmouth and BS in Chemistry and Biology from Duke University.
- William Guyer
William Guyer于2021年8月被任命为首席开发官。2015年3月至2021年8月，他担任吉利德全球医疗事务团队高级副总裁，负责制定创新战略，以推动化合物在包括传染病、肝病、癌症和炎症性疾病在内的广泛复杂疾病中从发现到商业化。他的工作包括设计、实施和支持公司和研究人员赞助的研究、合作研究、真实世界的数据生成和健康结果研究，以及吉利德整个药物组合中的科学和医学传播和教育计划。在加入吉利德之前，Guyer博士是南加州Kaiser Permanente的HIV药房和门诊输液中心服务总监。他是一名临床药剂师，拥有南加州大学的药学博士学位。
William Guyer,was named Chief Development Officer in August 2021.From March 2015 to August 2021, he served as Senior Vice President of Gilead's global Medical Affairs team, with responsibility for developing innovative strategies for advancing compounds from discovery to commercialization in a wide range of complex diseases, including infectious diseases, liver diseases, cancer and inflammatory disorders. His work included designing, implementing and supporting company- and investigator-sponsored studies, collaborative studies, real-world data generation and health outcomes research, as well as scientific and medical communications and education programs across Gilead's entire portfolio of medications. Prior to joining Gilead, Dr. Guyer was the Director of the HIV Pharmacy and Outpatient Infusion Center Services for Kaiser Permanente in Southern California. He is a clinical pharmacist and holds a Pharm.D. from the University of Southern California.- William Guyer于2021年8月被任命为首席开发官。2015年3月至2021年8月，他担任吉利德全球医疗事务团队高级副总裁，负责制定创新战略，以推动化合物在包括传染病、肝病、癌症和炎症性疾病在内的广泛复杂疾病中从发现到商业化。他的工作包括设计、实施和支持公司和研究人员赞助的研究、合作研究、真实世界的数据生成和健康结果研究，以及吉利德整个药物组合中的科学和医学传播和教育计划。在加入吉利德之前，Guyer博士是南加州Kaiser Permanente的HIV药房和门诊输液中心服务总监。他是一名临床药剂师，拥有南加州大学的药学博士学位。
- William Guyer,was named Chief Development Officer in August 2021.From March 2015 to August 2021, he served as Senior Vice President of Gilead's global Medical Affairs team, with responsibility for developing innovative strategies for advancing compounds from discovery to commercialization in a wide range of complex diseases, including infectious diseases, liver diseases, cancer and inflammatory disorders. His work included designing, implementing and supporting company- and investigator-sponsored studies, collaborative studies, real-world data generation and health outcomes research, as well as scientific and medical communications and education programs across Gilead's entire portfolio of medications. Prior to joining Gilead, Dr. Guyer was the Director of the HIV Pharmacy and Outpatient Infusion Center Services for Kaiser Permanente in Southern California. He is a clinical pharmacist and holds a Pharm.D. from the University of Southern California.
- Hazel Hunt
Hazel Hunt于2020年7月被任命为首席科学官。在此之前，她担任研究高级副总裁。从2002年到2011年，Hunt博士担任Argenta的化学和运营总监，在那里她与Corcept密切合作，并在发现Corcept的下一代选择性糖皮质激素受体拮抗剂和皮质醇调节剂产品组合方面发挥了不可或缺的作用。1994年至2002年，她任职于Celltech，最初担任药物化学组长，最终担任项目化学组长。1992年至1994年，她担任药物设计和开发中心研究员。在此之前，Hunt博士曾在葛兰素史克集团研究公司担任药物化学高级化学家。亨特博士获得澳大利亚国立大学化学一级荣誉学位和英国南安普顿大学合成有机化学博士学位。她还在牛津大学和加州大学欧文分校开展博士后工作。
Hazel Hunt,was named Chief Scientific Officer in July 2020. Prior to that she was Senior Vice President, Research.From 2002 to 2011, Dr. Hunt was Director of Chemistry and Operations at Argenta, where she worked closely with Corcept and played an integral role in the discovery of Corcept's portfolio of next-generation selective glucocorticoid receptor antagonists and cortisol modulators. From 1994 to 2002, she worked for Celltech, initially as a Group Leader in Medicinal Chemistry and ultimately as Section Leader, Project Chemistry. From 1992 to 1994, she served as a Research Fellow at The Centre for Drug Design and Development. Before that Dr. Hunt worked at Glaxo Group Research as a Senior Chemist in Medicinal Chemistry. Dr. Hunt received a first-class honors degree in chemistry from the Australian National University and a Ph.D. in synthetic organic chemistry from the University of Southampton, UK. She also carried out postdoctoral work at Oxford University and the University of California at Irvine.- Hazel Hunt于2020年7月被任命为首席科学官。在此之前，她担任研究高级副总裁。从2002年到2011年，Hunt博士担任Argenta的化学和运营总监，在那里她与Corcept密切合作，并在发现Corcept的下一代选择性糖皮质激素受体拮抗剂和皮质醇调节剂产品组合方面发挥了不可或缺的作用。1994年至2002年，她任职于Celltech，最初担任药物化学组长，最终担任项目化学组长。1992年至1994年，她担任药物设计和开发中心研究员。在此之前，Hunt博士曾在葛兰素史克集团研究公司担任药物化学高级化学家。亨特博士获得澳大利亚国立大学化学一级荣誉学位和英国南安普顿大学合成有机化学博士学位。她还在牛津大学和加州大学欧文分校开展博士后工作。
- Hazel Hunt,was named Chief Scientific Officer in July 2020. Prior to that she was Senior Vice President, Research.From 2002 to 2011, Dr. Hunt was Director of Chemistry and Operations at Argenta, where she worked closely with Corcept and played an integral role in the discovery of Corcept's portfolio of next-generation selective glucocorticoid receptor antagonists and cortisol modulators. From 1994 to 2002, she worked for Celltech, initially as a Group Leader in Medicinal Chemistry and ultimately as Section Leader, Project Chemistry. From 1992 to 1994, she served as a Research Fellow at The Centre for Drug Design and Development. Before that Dr. Hunt worked at Glaxo Group Research as a Senior Chemist in Medicinal Chemistry. Dr. Hunt received a first-class honors degree in chemistry from the Australian National University and a Ph.D. in synthetic organic chemistry from the University of Southampton, UK. She also carried out postdoctoral work at Oxford University and the University of California at Irvine.
- Joseph D. Lyon
Joseph D. Lyon，于2024年2月被任命为首席会计和技术官。在此之前，他于2020年7月至2024年1月担任Corcept的首席会计官，在此之前担任副总裁、公司控制人。里昂先生于2012年7月加入公司担任财务及会计总监。里昂先生于2011年7月至2012年6月在ZINFI Technologies，Inc.担任全球公司财务总监和总经理职务，并于2006年1月至2011年6月在Connor Group担任业务发展和运营总监职务。在此之前，里昂先生于2004年7月至2006年6月期间担任安永会计师事务所的审计师。里昂先生是一名注册会计师，曾获得犹他大学会计学学士和硕士学位，毕业于哈佛商学院行政商务综合管理课程。
Joseph D. Lyon,was named Chief Accounting and Technology Officer in February 2024. Prior to that he was Corcept's Chief Accounting Officer from July 2020 to January 2024 and before that he was Vice President, Corporate Controller. Mr. Lyon joined the Company as Director of Finance and Accounting in July 2012. Mr. Lyon held the positions of Worldwide Corporate Controller and General Manager at ZINFI Technologies, Inc. from July 2011 to June 2012 and Director of Business Development and Operations at Connor Group from January 2006 to June 2011. Prior to that, Mr. Lyon was an auditor at Ernst & Young, Inc. from July 2004 to June 2006. Mr. Lyon is a Certified Public Accountant and earned a B.A. and Masters in Accounting from the University of Utah, and is a graduate of Harvard Business School's Executive Business General Management Program.- Joseph D. Lyon，于2024年2月被任命为首席会计和技术官。在此之前，他于2020年7月至2024年1月担任Corcept的首席会计官，在此之前担任副总裁、公司控制人。里昂先生于2012年7月加入公司担任财务及会计总监。里昂先生于2011年7月至2012年6月在ZINFI Technologies，Inc.担任全球公司财务总监和总经理职务，并于2006年1月至2011年6月在Connor Group担任业务发展和运营总监职务。在此之前，里昂先生于2004年7月至2006年6月期间担任安永会计师事务所的审计师。里昂先生是一名注册会计师，曾获得犹他大学会计学学士和硕士学位，毕业于哈佛商学院行政商务综合管理课程。
- Joseph D. Lyon,was named Chief Accounting and Technology Officer in February 2024. Prior to that he was Corcept's Chief Accounting Officer from July 2020 to January 2024 and before that he was Vice President, Corporate Controller. Mr. Lyon joined the Company as Director of Finance and Accounting in July 2012. Mr. Lyon held the positions of Worldwide Corporate Controller and General Manager at ZINFI Technologies, Inc. from July 2011 to June 2012 and Director of Business Development and Operations at Connor Group from January 2006 to June 2011. Prior to that, Mr. Lyon was an auditor at Ernst & Young, Inc. from July 2004 to June 2006. Mr. Lyon is a Certified Public Accountant and earned a B.A. and Masters in Accounting from the University of Utah, and is a graduate of Harvard Business School's Executive Business General Management Program.
- Sean Maduck
Sean Maduck，于2022年4月被任命为Corcept内分泌科总裁。在此之前，他是首席商务官，在此之前，他是Corcept Therapeutics Incorporated商业高级副总裁。Maduck先生于2012年加入Corcept，拥有公司12年的制药、生物技术和管理经验。2002年至2012年，他在基因泰克担任财务、投资组合规划和商业职能部门的职务。在加入基因泰克之前，他是W.R. Hambrecht +公司的投资银行分析师。2012年至2022年，Maduck先生担任癌症支持社区–旧金山湾区的董事会成员。Maduck先生在达特茅斯学院获得了A.B.学位，在达特茅斯学院的Thayer工程学院获得了生物医学工程学士学位，并在斯坦福大学商学院获得了管理学硕士学位。
Sean Maduck,was named President, Corcept Endocrinology in April 2022. Prior to that he was Chief Commercial Officer and before that he was Corcept Therapeutics Incorporated Senior Vice President, Commercial. Mr. Maduck joined Corcept in 2012, hasing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. From 2012 to 2022, Mr. Maduck served on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an A.B. from Dartmouth College, a B.E. in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.- Sean Maduck，于2022年4月被任命为Corcept内分泌科总裁。在此之前，他是首席商务官，在此之前，他是Corcept Therapeutics Incorporated商业高级副总裁。Maduck先生于2012年加入Corcept，拥有公司12年的制药、生物技术和管理经验。2002年至2012年，他在基因泰克担任财务、投资组合规划和商业职能部门的职务。在加入基因泰克之前，他是W.R. Hambrecht +公司的投资银行分析师。2012年至2022年，Maduck先生担任癌症支持社区–旧金山湾区的董事会成员。Maduck先生在达特茅斯学院获得了A.B.学位，在达特茅斯学院的Thayer工程学院获得了生物医学工程学士学位，并在斯坦福大学商学院获得了管理学硕士学位。
- Sean Maduck,was named President, Corcept Endocrinology in April 2022. Prior to that he was Chief Commercial Officer and before that he was Corcept Therapeutics Incorporated Senior Vice President, Commercial. Mr. Maduck joined Corcept in 2012, hasing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. From 2012 to 2022, Mr. Maduck served on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an A.B. from Dartmouth College, a B.E. in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.
- Charles Robb
Charles Robb，在担任公司首席财务官超过九年后，于2021年3月被任命为首席商务官。Robb先生在执行管理、运营和财务方面拥有30多年的经验。从2005年4月到2011年8月，Robb先生担任Fitness Anywhere，Inc.的运营、行政和财务高级副总裁，该公司是一家在美国、欧洲和亚洲开展业务的健身设备和培训公司。2003年至2005年，Robb先生从事私人执业法律工作。2000年至2002年，他担任Citadon，Inc.高级副总裁。他还曾于1998年至1999年在野村资产资本公司担任业务发展职务，并于1996年至1998年在Legal Research Network，Inc.担任销售和市场营销职务。1992年至1996年，Robb先生在Howard，Rice，Nemerovski，Canady，Falk & Rabkin从事法律工作。Robb先生在耶鲁大学获得了英语和政治哲学学士学位，并在哈佛法学院获得了法学博士学位，他是哈佛法律评论的成员。
Charles Robb,was named as Chief Business Officer in March 2021 after serving more than nine years as the Company's Chief Financial Officer. Mr. Robb has more than 30 years of experience in executive management, operations and finance. From April 2005 through August 2011, Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc., from 1996 to 1998. From 1992 to 1996, Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School, where he was a member of the Harvard Law Review.- Charles Robb，在担任公司首席财务官超过九年后，于2021年3月被任命为首席商务官。Robb先生在执行管理、运营和财务方面拥有30多年的经验。从2005年4月到2011年8月，Robb先生担任Fitness Anywhere，Inc.的运营、行政和财务高级副总裁，该公司是一家在美国、欧洲和亚洲开展业务的健身设备和培训公司。2003年至2005年，Robb先生从事私人执业法律工作。2000年至2002年，他担任Citadon，Inc.高级副总裁。他还曾于1998年至1999年在野村资产资本公司担任业务发展职务，并于1996年至1998年在Legal Research Network，Inc.担任销售和市场营销职务。1992年至1996年，Robb先生在Howard，Rice，Nemerovski，Canady，Falk & Rabkin从事法律工作。Robb先生在耶鲁大学获得了英语和政治哲学学士学位，并在哈佛法学院获得了法学博士学位，他是哈佛法律评论的成员。
- Charles Robb,was named as Chief Business Officer in March 2021 after serving more than nine years as the Company's Chief Financial Officer. Mr. Robb has more than 30 years of experience in executive management, operations and finance. From April 2005 through August 2011, Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc., from 1996 to 1998. From 1992 to 1996, Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School, where he was a member of the Harvard Law Review.
- Joseph K. Belanoff
Joseph K. Belanoff，他是公司的共同创办人，自1999年起担任公司董事会成员和首席执行官，自2014年1月1日为公司的总裁。他目前是临床教员，自1992年以来在斯坦福大学的精神病学和行为科学系担任多个职位。他收到了阿默斯特学院的学士学位和哥伦比亚大学的医生和外科医生学院的医学博士学位。
Joseph K. Belanoff,is a co-founder of Company and has served as a member of Board and Chief Executive Officer since Corcept's inception in 1999, and as President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions in the Department of Psychiatry and Behavioral Sciences since 1992. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University's College of Physicians & Surgeons.- Joseph K. Belanoff，他是公司的共同创办人，自1999年起担任公司董事会成员和首席执行官，自2014年1月1日为公司的总裁。他目前是临床教员，自1992年以来在斯坦福大学的精神病学和行为科学系担任多个职位。他收到了阿默斯特学院的学士学位和哥伦比亚大学的医生和外科医生学院的医学博士学位。
- Joseph K. Belanoff,is a co-founder of Company and has served as a member of Board and Chief Executive Officer since Corcept's inception in 1999, and as President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions in the Department of Psychiatry and Behavioral Sciences since 1992. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University's College of Physicians & Surgeons.
- G. Charles Robb
G. Charles Robb，自2011年9月起，他担任财务总监，并自2014年1月担任秘书。他拥有超过25年的执行管理，营运及财务经验。从2005年4月至2011年8月他担任Fitness Anywhere公司（一个私人固定资产投资，私人健身器材和培训公司，在美国，欧洲和亚洲有业务）的运营，行政和财务高级副总裁。从2003年至2005年他从事法律的私人工作。从2000年到2002年，他是Citadon公司高级副总裁。从1998年至1999年他还担任了 Normura Asset Capital 公司的业务开发职位，1996至1998年担任 Legal Research Network公司的销售和营销的职位。从1992年到1996年他在 Howard, Rice, Nemerovski, Canady, Falk & Rabkin从事法律工作。他获得了耶鲁大学的英语和政治哲学文学士学位和哈佛法学院的法学博士学位，在那里他是哈佛法律评论的一员。
G. Charles Robb has served as Chief Financial Officer since September 2011 and as Secretary since January 2014. From April 2005 through August 2011 Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005 Mr. Robb was engaged in the private practice of law. From 2000 to 2002 he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996 Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School.- G. Charles Robb，自2011年9月起，他担任财务总监，并自2014年1月担任秘书。他拥有超过25年的执行管理，营运及财务经验。从2005年4月至2011年8月他担任Fitness Anywhere公司（一个私人固定资产投资，私人健身器材和培训公司，在美国，欧洲和亚洲有业务）的运营，行政和财务高级副总裁。从2003年至2005年他从事法律的私人工作。从2000年到2002年，他是Citadon公司高级副总裁。从1998年至1999年他还担任了 Normura Asset Capital 公司的业务开发职位，1996至1998年担任 Legal Research Network公司的销售和营销的职位。从1992年到1996年他在 Howard, Rice, Nemerovski, Canady, Falk & Rabkin从事法律工作。他获得了耶鲁大学的英语和政治哲学文学士学位和哈佛法学院的法学博士学位，在那里他是哈佛法律评论的一员。
- G. Charles Robb has served as Chief Financial Officer since September 2011 and as Secretary since January 2014. From April 2005 through August 2011 Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005 Mr. Robb was engaged in the private practice of law. From 2000 to 2002 he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996 Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School.